CYB5R2

Summary

CYB5R2 (cytochrome b5 reductase 2, HGNC:24376) is a protein-coding gene on chromosome 11p15.4, encoding NADH-cytochrome b5 reductase 2 (Q6BCY4). NADH-cytochrome b5 reductases are involved in desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction.

The protein encoded by this gene belongs to the flavoprotein pyridine nucleotide cytochrome reductase family of proteins. Cytochrome b-type NAD(P)H oxidoreductases are implicated in many processes including cholesterol biosynthesis, fatty acid desaturation and elongation, and respiratory burst in neutrophils and macrophages. Cytochrome b5 reductases have soluble and membrane-bound forms that are the product of alternative splicing. In animal cells, the membrane-bound form binds to the endoplasmic reticulum, where it is a member of a fatty acid desaturation complex. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 51700 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 74 total
• MANE Select transcript: NM_016229

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24376
Approved symbol	CYB5R2
Name	cytochrome b5 reductase 2
Location	11p15.4
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000166394
Ensembl biotype	protein_coding
OMIM	608342
Entrez	51700

Gene structure

Transcript identifiers

Ensembl transcripts: 32 — 25 protein_coding, 5 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000299498, ENST00000436351, ENST00000524608, ENST00000524790, ENST00000525307, ENST00000526084, ENST00000527542, ENST00000528585, ENST00000531096, ENST00000532621, ENST00000532920, ENST00000533558, ENST00000534443, ENST00000534698, ENST00000872666, ENST00000872667, ENST00000872668, ENST00000872669, ENST00000872670, ENST00000872671, ENST00000872672, ENST00000872673, ENST00000872674, ENST00000872675, ENST00000917892, ENST00000917893, ENST00000917894, ENST00000917895, ENST00000917896, ENST00000917897, ENST00000954656, ENST00000954657

RefSeq mRNA: 3 — MANE Select: NM_016229 NM_001302826, NM_001302827, NM_016229

CCDS: CCDS7780

Canonical transcript exons

ENST00000299498 — 9 exons

Exon	Start	End
ENSE00001102585	7666451	7666550
ENSE00002160342	7673419	7673500
ENSE00003509477	7672748	7672891
ENSE00003522259	7667728	7667813
ENSE00003570840	7669625	7669731
ENSE00003596177	7672451	7672523
ENSE00003661356	7668478	7668561
ENSE00003687542	7665104	7665546
ENSE00003787362	7669205	7669334

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 98.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.9797 / max 124.9505, expressed in 1175 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
118475	3.4267	845
118466	3.1100	1049
118474	0.2759	144
118468	0.0711	11
118467	0.0398	7
118476	0.0255	9
118469	0.0171	5
118465	0.0137	2

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	98.48	gold quality
right testis	UBERON:0004534	98.39	gold quality
tibial nerve	UBERON:0001323	98.14	gold quality
testis	UBERON:0000473	96.73	gold quality
sperm	CL:0000019	96.29	gold quality
sural nerve	UBERON:0015488	95.78	gold quality
male germ cell	CL:0000015	95.35	gold quality
skin of abdomen	UBERON:0001416	94.77	gold quality
skin of leg	UBERON:0001511	94.22	gold quality
adult organism	UBERON:0007023	93.42	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	92.69	gold quality
zone of skin	UBERON:0000014	92.48	gold quality
minor salivary gland	UBERON:0001830	91.49	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.26	gold quality
body of uterus	UBERON:0009853	90.92	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	89.78	gold quality
left ovary	UBERON:0002119	89.51	gold quality
mouth mucosa	UBERON:0003729	89.40	gold quality
spinal cord	UBERON:0002240	89.29	gold quality
saliva-secreting gland	UBERON:0001044	88.89	gold quality
right ovary	UBERON:0002118	88.05	gold quality
ectocervix	UBERON:0012249	87.97	gold quality
corpus callosum	UBERON:0002336	87.85	gold quality
putamen	UBERON:0001874	87.74	gold quality
endocervix	UBERON:0000458	87.73	gold quality
lower esophagus mucosa	UBERON:0035834	87.40	gold quality
esophagus mucosa	UBERON:0002469	87.28	gold quality
calcaneal tendon	UBERON:0003701	87.11	gold quality
ascending aorta	UBERON:0001496	87.07	gold quality
ovary	UBERON:0000992	87.02	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

15 targeting CYB5R2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-4663	99.62	65.33	957
HSA-MIR-6832-3P	99.52	70.44	1726
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-146A-3P	99.13	68.99	1881
HSA-MIR-129-1-3P	98.86	68.41	779
HSA-MIR-129-2-3P	98.86	68.41	779
HSA-MIR-589-5P	98.72	66.96	927
HSA-MIR-302F	98.44	69.02	1776
HSA-MIR-1245B-3P	98.01	68.91	1387
HSA-MIR-4475	97.36	66.95	761
HSA-MIR-6849-3P	97.25	64.57	1371
HSA-MIR-4714-5P	97.04	67.76	955
HSA-MIR-1233-3P	96.81	65.44	573

Literature-anchored findings (GeneRIF, showing 6)

• CYB5R2 is a key enzyme involved in the mediation of NADH-induced redox activity in human spermatozoa. (PMID:15858218)
• findings suggest that CYB5R2 may be a functional tumor suppressor gene, frequently inactivated by hypermethylation of its promoter in nasopharyngeal carcinoma (PMID:24338690)
• Study showed that multifocal or multicentric glioblastomas have some underlying genetic and epigenetic characteristics that are associated with poor prognosis and that CYB5R2 is a new epigenetic marker for glioblastoma prognosis (PMID:26323991)
• Intratumoral Heterogeneity for Inactivating Frameshift Mutation of CYB5R2 Gene in Colorectal Cancers. (PMID:29532410)
• Long non-coding RNA MEG3 inhibits neovascularization in diabetic retinopathy by regulating microRNA miR-6720-5p and cytochrome B5 reductase 2. (PMID:34978518)
• NADH-Cytochrome B5 reductase 2 suppresses retinal vascular dysfunction through regulation of vascular endothelial growth factor A in diabetic retinopathy. (PMID:35820466)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	cyb5r2	ENSDARG00000051925
mus_musculus	Cyb5r2	ENSMUSG00000048065
rattus_norvegicus	Cyb5r2	ENSRNOG00000019751
drosophila_melanogaster	CG5946	FBGN0036211
caenorhabditis_elegans		WBGENE00020267
caenorhabditis_elegans		WBGENE00020268

Paralogs (5): CYB5R4 (ENSG00000065615), CYB5R3 (ENSG00000100243), OXNAD1 (ENSG00000154814), CYB5R1 (ENSG00000159348), CYB5RL (ENSG00000215883)

Protein

Protein identifiers

NADH-cytochrome b5 reductase 2 — Q6BCY4 (reviewed: Q6BCY4)

All UniProt accessions (5): E9PIV9, E9PMI2, E9PQW2, E9PRM4, Q6BCY4

UniProt curated annotations — full annotation on UniProt →

Function. NADH-cytochrome b5 reductases are involved in desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction. Responsible for NADH-dependent lucigenin chemiluminescence in spermatozoa by reducing both lucigenin and 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-[2,4-disulfophenyl]-2H tetrazolium monosodium salt (WST-1).

Tissue specificity. Restricted expression.

Similarity. Belongs to the flavoprotein pyridine nucleotide cytochrome reductase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6BCY4-1	1	yes
Q6BCY4-2	2

RefSeq proteins (3): NP_001289755, NP_001289756, NP_057313* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001433	OxRdtase_FAD/NAD-bd	Domain
IPR001709	Flavoprot_Pyr_Nucl_cyt_Rdtase	Domain
IPR001834	CBR-like	Family
IPR008333	Cbr1-like_FAD-bd_dom	Domain
IPR017927	FAD-bd_FR_type	Domain
IPR017938	Riboflavin_synthase-like_b-brl	Homologous_superfamily
IPR039261	FNR_nucleotide-bd	Homologous_superfamily

Pfam: PF00175, PF00970

Enzyme classification (BRENDA):

• EC 1.6.2.2 — cytochrome-b5 reductase (BRENDA: 34 organisms, 101 substrates, 111 inhibitors, 300 Km, 221 kcat entries)

Substrate kinetics (BRENDA)

23 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
NADH	0.0002–3.32	94
FERRICYANIDE	0.0006–4.35	72
FERRICYTOCHROME B5	—	66
CYTOCHROME B5	0.0011–0.042	19
NADPH	0.001–7.69	17
FERROCYTOCHROME B5	0.001–0.107	6
FERRICYTOCHOME B5	0.01–0.013	4
FERRICYTOCHROME C	0.0003–0.007	3
OXIDIZED 2,6-DICHLOROPHENOLINDOPHENOL	0.328–0.83	2
1,4-NAPHTHOQUINONE	0.0098	1
2-HYDROXYESTRADIOL	0.0026	1
2-METHYL-1,4-NAPHTHOQUINONE	0.077	1
9,10-PHENANTHRENEQUINONE	0.0057	1
AQUACOBALAMIN	0.0419	1
BENZAMIDOXIME	0.63	1

Catalyzed reactions (Rhea), 1 shown:

• 2 Fe(III)-[cytochrome b5] + NADH = 2 Fe(II)-[cytochrome b5] + NAD(+) + H(+) (RHEA:46680)

UniProt features (11 total): sequence conflict 2, binding site 2, modified residue 2, sequence variant 2, chain 1, domain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6BCY4-F1	95.73	0.95

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 107–137; 146–181

Post-translational modifications (2): 17, 18

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1237044	Erythrocytes take up carbon dioxide and release oxygen
R-HSA-1480926	O2/CO2 exchange in erythrocytes
R-HSA-382551	Transport of small molecules

MSigDB gene sets: 99 (showing top): ONDER_CDH1_TARGETS_3_DN, YORDY_RECIPROCAL_REGULATION_BY_ETS1_AND_SP100_DN, YANG_BREAST_CANCER_ESR1_DN, GOBP_STEROID_BIOSYNTHETIC_PROCESS, GOBP_ORGANIC_ANION_TRANSPORT, GOBP_BICARBONATE_TRANSPORT, GOBP_LIPID_METABOLIC_PROCESS, TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_DN, GOBP_LIPID_BIOSYNTHETIC_PROCESS, SENESE_HDAC1_TARGETS_UP, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_NAD_P_H, GOBP_STEROL_BIOSYNTHETIC_PROCESS, VANTVEER_BREAST_CANCER_ESR1_DN, GOBP_STEROID_METABOLIC_PROCESS, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK

GO Biological Process (5): bicarbonate transport (GO:0015701), sterol biosynthetic process (GO:0016126), lipid metabolic process (GO:0006629), steroid biosynthetic process (GO:0006694), steroid metabolic process (GO:0008202)

GO Molecular Function (5): cytochrome-b5 reductase activity, acting on NAD(P)H (GO:0004128), FAD binding (GO:0071949), cytochrome-b5 reductase activity, acting on NADH (GO:0090524), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (4): nucleus (GO:0005634), mitochondrion (GO:0005739), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
O2/CO2 exchange in erythrocytes	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
transport	1
steroid biosynthetic process	1
sterol metabolic process	1
primary metabolic process	1
steroid metabolic process	1
lipid biosynthetic process	1
lipid metabolic process	1
oxidoreductase activity, acting on NAD(P)H, heme protein as acceptor	1
flavin adenine dinucleotide binding	1
cytochrome-b5 reductase activity, acting on NAD(P)H	1
binding	1
catalytic activity	1
cytoplasm	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1272 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CYB5R2	CYB5B	O43169	993
CYB5R2	CYB5A	P00167	992
CYB5R2	SCD	O00767	818
CYB5R2	POR	P16435	612
CYB5R2	CYP51A1	Q16850	581
CYB5R2	DHODH	Q02127	502
CYB5R2	SUOX	P51687	470
CYB5R2	ZNF614	Q8N883	462
CYB5R2	CCNYL1	Q8N7R7	433
CYB5R2	CLRN3	Q8NCR9	425
CYB5R2	TNFRSF13B	O14836	418
CYB5R2	NQO1	P15559	418
CYB5R2	ZPBP2	Q6X784	412
CYB5R2	TUBG2	Q9NRH3	410
CYB5R2	CYP27C1	Q4G0S4	410

IntAct

29 interactions, top by confidence:

A	B	Type	Score
CYB5R2	TRIP13	psi-mi:“MI:0915”(physical association)	0.670
TRIP13	CYB5R2	psi-mi:“MI:0915”(physical association)	0.670
PSMC6	CYB5R2	psi-mi:“MI:0915”(physical association)	0.560
GOLGA2	CYB5R2	psi-mi:“MI:0915”(physical association)	0.560
CYB5R2	TRAF2	psi-mi:“MI:0915”(physical association)	0.560
CYB5R2	TRAF1	psi-mi:“MI:0915”(physical association)	0.560
CYB5R2	CDC23	psi-mi:“MI:0915”(physical association)	0.560
TRAF2	CYB5R2	psi-mi:“MI:0915”(physical association)	0.560
CDC23	CYB5R2	psi-mi:“MI:0915”(physical association)	0.560
CYB5R2	GOLGA2	psi-mi:“MI:0915”(physical association)	0.560
TRAF1	CYB5R2	psi-mi:“MI:0915”(physical association)	0.560
FFAR2	CYB5R2	psi-mi:“MI:0915”(physical association)	0.370
OR2A4	A2ML1	psi-mi:“MI:0914”(association)	0.350
CCR1	UBA6	psi-mi:“MI:0914”(association)	0.350
PINK1	A2ML1	psi-mi:“MI:0914”(association)	0.350
AGPAT1	A2ML1	psi-mi:“MI:0914”(association)	0.350
SARAF	A2ML1	psi-mi:“MI:0914”(association)	0.350
MYCBP	A2ML1	psi-mi:“MI:0914”(association)	0.350
SMPD2	A2ML1	psi-mi:“MI:0914”(association)	0.350
CYB5R2	COIL	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (34): CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid), CYB5R2 (Two-hybrid)

ESM2 similar proteins: A1C7E9, A1DHW1, A2QCV4, A4R935, A5DQ25, A6R2K7, A6ZVM6, O74557, P00387, P04175, P07514, P0CP14, P0CP15, P16435, P19618, P20070, P37039, P38626, P83686, Q07994, Q0CY37, Q0P487, Q0UEY4, Q0X0E5, Q1DWN4, Q27597, Q2UFN3, Q3KNK3, Q3SYT8, Q4PGW7, Q4X0B5, Q54NC1, Q59P03, Q5AZB4, Q5BJ68, Q5EB81, Q5PQA4, Q5ZHX7, Q60HG4, Q6AY12

Diamond homologs: A0A286R227, A1C7E9, A1DHW1, A2QCV4, A3GF86, A3LT66, A4QR21, A4R935, A5DQ25, A5E7U2, A6R2K7, A6ZVM6, A7TNL7, B0CQN7, O74557, P00387, P07514, P07850, P08509, P08619, P0CP14, P0CP15, P11035, P11605, P11832, P16081, P17569, P17570, P17571, P20070, P22945, P23312, P27783, P27967, P27968, P27969, P36841, P36842, P36858, P36859

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	2
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1495 predictions. Top by Δscore:

Variant	Effect	Δscore
11:7668643:C:CA	donor_gain	1.0000
11:7669620:TTTA:T	donor_loss	1.0000
11:7669621:TTAC:T	donor_loss	1.0000
11:7669622:TAC:T	donor_loss	1.0000
11:7669623:AC:A	donor_loss	1.0000
11:7672445:GCTCA:G	donor_loss	1.0000
11:7672446:CTCA:C	donor_loss	1.0000
11:7672447:TCA:T	donor_loss	1.0000
11:7672448:CACCT:C	donor_loss	1.0000
11:7672449:A:C	donor_loss	1.0000
11:7672450:C:T	donor_loss	1.0000
11:7672744:TTAC:T	donor_loss	1.0000
11:7672745:TACCT:T	donor_loss	1.0000
11:7672746:ACC:A	donor_loss	1.0000
11:7672747:C:A	donor_loss	1.0000
11:7672747:CCT:C	donor_gain	1.0000
11:7672749:T:TA	donor_gain	1.0000
11:7665542:CCAGC:C	acceptor_gain	0.9900
11:7665543:CAGC:C	acceptor_gain	0.9900
11:7665543:CAGCC:C	acceptor_gain	0.9900
11:7665545:GCCTG:G	acceptor_loss	0.9900
11:7665546:CCTGA:C	acceptor_loss	0.9900
11:7665547:C:CC	acceptor_gain	0.9900
11:7665547:C:CG	acceptor_loss	0.9900
11:7665548:T:A	acceptor_loss	0.9900
11:7666547:CTGT:C	acceptor_gain	0.9900
11:7667723:CTGA:C	donor_loss	0.9900
11:7667724:TGACC:T	donor_loss	0.9900
11:7667725:GACC:G	donor_loss	0.9900
11:7667727:C:CA	donor_loss	0.9900

AlphaMissense

1826 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:7672498:A:G	F35S	0.989
11:7669285:G:A	T103I	0.987
11:7672495:C:G	R36P	0.986
11:7669635:A:G	L83P	0.984
11:7672504:C:G	R33P	0.984
11:7665544:A:G	W221R	0.983
11:7665544:A:T	W221R	0.983
11:7669625:C:A	K86N	0.983
11:7669625:C:G	K86N	0.983
11:7667744:A:G	L181P	0.982
11:7669238:C:G	G119R	0.982
11:7669238:C:T	G119R	0.982
11:7665456:C:T	G250D	0.981
11:7665522:A:T	V228D	0.981
11:7669627:T:C	K86E	0.981
11:7669237:C:T	G119E	0.980
11:7669722:A:T	V54D	0.980
11:7667813:C:T	G158D	0.979
11:7669671:G:T	P71H	0.979
11:7669629:A:T	I85K	0.978
11:7672761:A:G	L22S	0.978
11:7668489:G:T	A154D	0.977
11:7672491:A:C	F37L	0.977
11:7672491:A:T	F37L	0.977
11:7672493:A:G	F37L	0.977
11:7669276:A:G	L106S	0.975
11:7669682:C:A	R67S	0.975
11:7669682:C:G	R67S	0.975
11:7672515:G:C	S29R	0.974
11:7672515:G:T	S29R	0.974

dbSNP variants (sampled 300 via entrez): RS1000015876 (11:7674105 A>G,T), RS1000409569 (11:7666709 C>A,G), RS1000913302 (11:7674638 G>A), RS1000963864 (11:7674962 T>C), RS1001128291 (11:7670785 G>A), RS1001310805 (11:7672189 T>G), RS1001356570 (11:7671969 G>A,C), RS1001408757 (11:7671836 C>T), RS1001476393 (11:7670628 T>C), RS1001638909 (11:7666759 A>C), RS1002079184 (11:7665905 G>T), RS1002382500 (11:7668237 C>G,T), RS1002475156 (11:7674554 T>G), RS1002516141 (11:7668241 G>C,T), RS1003033322 (11:7673079 G>T)

Disease associations

OMIM: gene MIM:608342 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002143_7	Blood pressure	6.000000e-06
GCST009391_103	Metabolite levels	6.000000e-06
GCST010725_20	Malaria	4.000000e-69
GCST010725_33	Malaria	2.000000e-67
GCST010725_51	Malaria	1.000000e-55

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure
EFO:0009767	glycine measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tetrachlorodibenzodioxin	increases expression, affects expression	3
Benzo(a)pyrene	increases methylation, increases expression	2
Smoke	decreases expression, decreases reaction	2
Tobacco Smoke Pollution	affects expression, increases expression	2
Tretinoin	increases expression	2
Particulate Matter	increases expression, affects methylation, increases abundance	2
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
pirinixic acid	decreases expression, increases activity, affects binding	1
bisphenol A	decreases methylation	1
decabromobiphenyl ether	decreases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
sodium arsenite	increases expression	1
butyraldehyde	increases expression	1
cupric oxide	increases expression	1
pentanal	increases expression	1
ICG 001	increases expression	1
mirdametinib	decreases expression, affects cotreatment	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
MRK 003	decreases expression	1
(+)-JQ1 compound	affects cotreatment, decreases expression	1
Resveratrol	increases expression	1
Temozolomide	increases expression	1
Decitabine	decreases expression, decreases reaction	1
Sunitinib	decreases expression	1
Arsenic Trioxide	decreases expression	1
Fulvestrant	increases methylation	1
Air Pollutants	affects methylation, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.